...
CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS

March 06, 2025
MAP Communication
MAP Communication

CYSTIC FIBROSIS: A MAJOR STEP FORWARD FOR PATIENTS

CHMP favourable opinion to extend the therapeutic indication of the two medicinal products Kaftrio and Kalydeco

Very important news has come from the Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) for the future of many people affected by Cystic Fibrosis: the agency has in fact recommended extending the therapeutic indication of two medicines, Kaftrio (ivacaftor-tezacaftor-elexacaftor) and Kalydeco (ivacaftor), for the treatment of the disease, including their use in combination for patients aged two years and older who have at least one non-class I mutation (stop mutations) in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. The extension of the indication will make it possible to treat all patients who may benefit from these therapies, meaning that approximately 95-97% of patients with cystic fibrosis in the European Union (EU) could benefit. This represents an increase of 15-17% over the previous indication.

The CHMP recommendation is based on the evaluation of efficacy and safety data from clinical and in vitro (laboratory) studies, including a randomised placebo-controlled study, an open-arm study, data from a real evidence study conducted by the Cystic Fibrosis Foundation of the United States, as well as literature data obtained through a compassionate use programme in France.

“This opinion is a very important step – states Antonio Guarini, President of the Italian Cystic Fibrosis League ODV – As a leading association for patients and families in Italy, we have been following this process for some time: we will continue our commitment at the national level to ensure that more and more patients can access care that improves their quality of life”.

The favourable CHMP opinion represents an intermediate step for patient access to Kaftrio and Kalydeco. The next step is now awaited, which will decide on the extension of the therapeutic indication to the European level. Once the extension has been granted, price and reimbursement decisions will be taken at the level of each Member State, taking into account the possible role and use of these drugs in the context of their national health systems.

The full text is public on the EMA website: https://www.ema.europa.eu/en/news/combination-cystic-fibrosis-medicines-treat-patients-rare-mutations.